EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Measles epidemic and Salmonella outbreak cost nearly six million euros The most recent measles epidemic and outbreak of Salmonella Thomson due to smoked salmon have cost 3.9 and 1.7 million euros, respectively.
Half of the Dutch participate in sport weekly In 2014, 53% of people between the ages of 12 and 80 in the Netherlands participate in some type of sport weekly.
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
RIVM provides overview of the possible risks of bisphenol A RIVM has created an overview of the possible risks of Bisphenol A (BPA) for humans and the environment. BPA is a component of many different products and affects the endocrine system.
RIVM involvement in UN/EU missions RIVM-experts from the Environmental Assessment Unit (EAU) have undertaken two missions involving an emergency situation in the Solomon Islands and an environmental assessment in Georgia.
RIVM provides support during the Nuclear Security Summit RIVM is in a state of readiness to assist and support the fire brigade, the Dutch National Police Service (KLPD) and the Regional Emergency Health Organisation (GHOR) in the event of any disasters
No more complementary vaccinations against measles for children aged six months The measles epidemic, the first case of which occurred in the Netherlands in May 2013, is coming to an end.